An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

[1]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  C. Porta,et al.  A new patient‐focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options , 2011, BJU international.

[3]  N. Rioux-Leclercq,et al.  Recommandations en Onco-Urologie 2010 : Cancer du rein , 2010 .

[4]  Jean-Jacques Patard,et al.  EAU guidelines on renal cell carcinoma: the 2010 update. , 2010, European urology.

[5]  Norbert Hollaender,et al.  Phase 3 trial of everolimus for metastatic renal cell carcinoma , 2010, Cancer.

[6]  A. Ravaud,et al.  Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. , 2010, American journal of respiratory and critical care medicine.

[7]  M. Climent,et al.  Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma , 2010, Cancer and Metastasis Reviews.

[8]  J. Hajdenberg,et al.  Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America , 2010, Cancer.

[9]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Kibel.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2009 .

[11]  T. Choueiri,et al.  Targeted therapies: Sunitinib in RCC—expanded access equals expanded benefit? , 2009, Nature Reviews Clinical Oncology.

[12]  C. Porta,et al.  Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. , 2009, The Lancet. Oncology.

[13]  B. Rini.  Metastatic renal cell carcinoma: many treatment options, one patient. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T. D. de Reijke,et al.  EORTC-GU group expert opinion on metastatic renal cell cancer. , 2009, European journal of cancer.

[15]  P. Febbo,et al.  NCCN Task Force Report: mTOR inhibition in solid tumors. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[16]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[17]  D. Strumberg.  Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[19]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[20]  James Brugarolas,et al.  Renal-cell carcinoma--molecular pathways and therapies. , 2007, The New England journal of medicine.

[21]  S. Liou,et al.  Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  L. Schwartz,et al.  Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.